Work

A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.e13618

Authors: S. A. Ghamande, C. Lin, D. C. Cho, T. A. Coleman, I. Chaudhary, J. M. Cleary, M. H. Silverman, M. Kuo, W. Mach, Y. Tseng, S. C. Hsu, S. Goel

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2570518814

Cites:

Cited by: 5

Related to: 10